Resveratrol (3,5,4'-trihydroxystilbene, RES) is a natural product reported to display relevant and varied biological activity. However, its low bioavailability and rapid metabolism to its glucuronate and sulfate conjugates has opened a debate on the mechanisms underlying its bioactivity. At the same time, resveratrol derivatives and prodrugs are being developed to circumvent these difficulties. We have synthesized a series of resveratrol prodrugs and resveratrol metabolites and evaluated their cytotoxicity, VEGF expression and telomerase inhibition. One healthy (human embryonic kidney, HEK-293) and two tumoral cell lines (human colon HT-29 and breast adenocarcinoma MCF-7) were used for the assays. Cytotoxic measurements revealed that resveratrol glucosylated prodrugs 2-4 and piceid octanoate 7 were more cytotoxic than resveratrol itself and more interestingly piceid 2, resveratrol-3,5-diglucoside 3, and resveratrol-3,4'disulfate 10 combine relatively high cytotoxicity and high therapeutic safety margins. VEGF production in HT-29 cells was decreased by piceid 2 and resveratrol-3,4'disulfate 10 whereas resveratrol-3,5-diglucoside 3 and piceid octanoate 7 diminished it to a higher extent than resveratrol. Finally, 3 and 10 were also able to inhibit the expression of the hTERT gen that could be correlated to a lower transcription of the c-Myc gene for 3 but not for RES disulfate metabolite 10. In conclusion, resveratrol prodrugs such as resveratrol-3,5-diglucoside 3 could be promising candidates as anticancer drugs. In addition, RES sulphate metabolites have shown their own biological activity indicating they are not simply RES reservoirs.
INTRODUCTION
Resveratrol (trans-3,5,4′-trihydroxystilbene, 1, see Figure 1 ) is a phytoalexin generated in response to environmental stress or pathogenic attack in grapes, blueberries, peanuts, cocoa and plants such as the Japanese knotweed Polygonum cuspidatum. Resveratrol has raised a great attention due to its relevant and varied biological activity such as its cardiovascular protective properties (1), antiinflammatory activity (2) or its capacity to extend lifespan in a variety of species (3) . The cancer chemopreventive and chemotherapeutic potential of resveratrol has been demonstrated in different models of carcinogenesis in vitro and in vivo. It inhibits the proliferation of a variety of cancer cell lines (4) and in animal studies, resveratrol is able to interfere with the formation of azoxymethane-(AOM) induced aberrant crypt foci in rat colon (5) , reduce mammary tumour formation in Nmethyl-N-nitrosourea-(NMU) treated rats (6) or suppress prostate cancer in SV-40 tag rats (7) . In fact, extensive in vitro studies have revealed multiple intracellular targets of resveratrol, which affect cell growth, inflammation, apoptosis and metastasis (8) .
Tumor angiogenesis also plays a critical role in the development of cancer.
Resveratrol 1 and piceid (resveratrol-3-β-glucoside, 2) have shown to inhibit the formation of capillary-like tube formation from human umbilical vein endothelial cells (HUVEC) (9, 10) .
At the same time, vascular endothelial growth factor (VEGF) is crucial for angiogenesis and tumor growth, as it is involved in blood vessel development. In breast cancer cells, a significant decrease in extracellular levels of VEGF has been associated with apoptosis following resveratrol treatment (11 
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Figure 1
A relevant aspect observed in 90% of malignant tumors is the maintenance of the telomeres length within the cellular DNA through the expression of the telomerase reverse transcriptase (hTERT). This process allows cancer cells to elude the progressive shortening of the telomeres and finally avoid apoptosis. Resveratrol showed an inhibitory effect on MCF-7 tumor cell line mainly due to induce S-phase arrest and apoptosis in association with reduced expression of hTERT (12) .
However, as is the case with many polyphenols with putative anticancer properties, the bioavailability of resveratrol is very low (13) . Resveratrol is well absorbed but avidly glucuronidated and sulphated both in the liver and in intestinal epithelial cells (14) (15) (16) (17) . In order to counteract this effect, high doses of resveratrol have been used in cellular, animal and clinical studies. This could be the cause of toxicity observed in certain cases such as in a multiple myeloma study in humans where 5 grams a day of a formulation of resveratrol were administered.
The low amounts of resveratrol observed systemically have brought the debate on the possible contribution of the resveratrol metabolites to the in vivo biological activities attributed to resveratrol (13, 18) . It has been proposed that resveratrol metabolites could contribute as a resveratrol reservoir through their deconjugation or that resveratrol metabolites could enter the cell using ABC transporters and interact directly with different intracellular targets (19) .
Moreover, resveratrol prodrugs are being investigated as an alternative trying to increase resveratrol bioavailability (20) (21) (22) (23) (24) . We had previously prepared a family of resveratrol prodrugs and pro-prodrugs attaching glucosyl-or acyl-groups to resveratrol 1 or piceid 2 and examined their anti-inflammatory effect on an inflammatory bowel disease (IBD) mice model (25) . We observed that oral administration of
produced an increase delivery of resveratrol to the colon, prevented the rapid metabolism of resveratrol and reduced inflammation in a murine dextran sodium sulphate (DSS) model.
In the present study, we have measured cytotoxicity studies, VEGF expression and telomerase inhibition of five resveratrol prodrugs 3-7 modified with glucosyl-or acylgroups. The idea was to find out their potential as cancer chemopreventive or chemotherapeutic agents either if they act as such or as a resveratrol reservoir. In addition, we have synthesized three resveratrol sulphate metabolites 8-10 using an improved synthetic route. We have also tested their biological activity and compared it with resveratrol itself trying to shed some light on the controversy of resveratrol metabolites biological activity. 
CHEMISTRY
were synthesized by enzymatic acylation using Thermomyces lanuginosus lipase immobilized on granulated silica (Lipozyme TL IM) as reported earlier (25) .
Resveratrol sulphate metabolites 8-10 were synthesized following the strategy reported by Hoshino et al.(26) . First, TBDMS-protected resveratrol derivatives 11-15 were obtained from RES and each compound separated by flash column chromatography.
However, posterior sulphation of each RES derivative using SO3 . NMe3 as sulphating reagent under acetonitrile reflux followed by silyl deprotection resulted in very low yields (10-26%).
Difficulties may come from no completion of the sulphation reaction and the difficult purification of these highly polar products.
We have used instead microwave-assisted synthesis as reported by the group of Desai (27, 28) for highly sulphated organic scaffolds. TBDMS-protected resveratrol derivatives 11-13 were treated with SO3 . NMe3 and NEt3 in acetonitrile and microwaves applied at 100 ºC for 20-40 minutes (Scheme 1). The crude was purified using LH-20 chromatography and desilylation was carried out using KF in MeOH during 18 h. Final crude purification was carried out using reversed-phase chromatography to obtain 8-10 in good yields (73-89%).
Scheme 1 BIOLOGICAL RESULTS AND DISCUSSION
In vitro cytotoxicity. The cytotoxicity of resveratrol derivatives 2-7 and resveratrol sulphate metabolites 8-10 was evaluated in vitro against two cancer cell lines, the human colon adenocarcinoma HT-29 and the breast adenocarcinoma MCF-7 cell lines. In addition, one normal cell line, the human embryonic kidney cell line (HEK-293) was employed in the assays for comparison (29) . The standard MTT assay was used as described in the When piceid is compared with resveratrol, IC50 values were in the same range or higher (31, 33) . In our case, piceid IC50 values measured were in between those reported previously and in both cell lines (HT-29 and MCF-7) were lower than those obtained for resveratrol. The differences found in cytoxicity values for piceid may come from the different methodologies used to measure cell viability or from the different purity of piceid used in these studies.
It is important to remark that glucosyl resveratrol derivatives 2-4 tested are more toxic for tumoral cells than for normal ones, an obviously desirable feature. This can be better Table 1 ). The higher value of the α or the β coefficient, the higher is the therapeutic safety reservoir. This could also be the case in our assays for piceid 2 and the glycosylated RES derivatives 3 and 4. However, we observed previously (25) that glucosyl-or acylmodifications in resveratrol prodrugs 2, 3, 4, 6 and 7 retarded their metabolism in Caco-2 cells but were indeed metabolized to RES and its conjugates (glucuronates, sulfates, etc.) after 6-24h incubation times. Therefore, compounds 2-4, 6 and 7 seem to acting just as prodrugs delivering RES to the cells. (38) suggested that the differences reported on cytoxicity for the resveratrol metabolites could be due to the use of different assays to measure cell viability.
Resveratrol sulfate metabolites have been suggested to provide an intracellular pool for resveratrol generation (39) . Our results show that sulfate resveratrol metabolites are equally or more active as antiproliferative agents that RES itself pointing out they probably contribute to the in vivo biological activity observed for resveratrol.
Effect of resveratrol derivatives and sulfate metabolites on VEGF production. One of the key factors in the angiogenesis process is the release of VEGF from cancer cells. We decided to examine whether our resveratrol derivatives and metabolites were able to inhibit or at least decrease the activation of VEGF genes in HT-29 tumoral cells. We selected for this study glucosylated resveratrol compounds 2 and 3, piceid octanoate 7, and resveratrol sulphate metabolites 8, 9 and 10. Again, resveratrol 1 was used as the positive control. We determined VEGF protein production by ELISA in culture supernatants. A different mechanism seems to be used by metabolite 10 pointing out again the fact that resveratrol-3,4'-disulfate is not just a resveratrol reservoir but instead that this resveratrol metabolite displays its on biological responses. significance was evaluated using one-sample t-tests (P <0.001).
In conclusion, resveratrol derivatives 2, 3, 4 and 7 displayed higher antiproliferative and antiangiogenic activity than resveratrol itself and, at the same time, these compounds showed less toxicity in HEK-293 cells. Most probably these derivatives are acting as RES prodrugs, delivering more slowly resveratrol to the cancer cells and therefore, also delaying RES metabolism. In the case of resveratrol sulfate metabolites 8-10, we observed equal or higher cytotoxicity than resveratrol in HT-29 and MCF-7 cells together with lower toxicity in healthy human cells. The fact that that resveratrol disulfate 10 decreases VEGF secretion but no activity is observed for resveratrol monosulfates 8 and 9 seems to indicate an intrinsic activity of 10 more than just a resveratrol reservoir. Finally, resveratrol metabolite 10 seems to decrease hTERT expression via a different mechanism than resveratrol itself since 10 does Metabolites were purified by Sephadex LH-20 and RP-C18 chromatography.
Reaction Conditions
Glucosylated resveratrol derivatives
Resveratrol (1, RES) and piceid (trans-resveratrol-3-O-β-D-glucopyranoside, 2, PIC) are commercially available. Diglucosylated resveratrol derivatives 3 and 4 were prepared as reported previously (25) .
Acylated resveratrol derivatives
3-O-stearoyl-trans-resveratrol (5) was kindly provided by Dr. F. J. Plou. Briefly, preparation of 5 involves enzymatic acylation from RES using immobilized lipase from Alcaligenes sp.
(lipase QLG) as reported previously (48) . Piceid acyl derivatives (6-7) were also synthesized by enzymatic acylation as described earlier by our group (25) .
Resveratrol sulphate metabolites
General procedure for the microwave-assisted O-sulfonation and desylilation:
Microwave based sulfonation reactions were performed using a microwave synthesizer in Genes were amplified by use of a thermal cycler and StepOnePlus ™ Taqman ® probes.
TaqMan ® Gene Expression Master Mix Fast containing the appropriate buffer for the amplification conditions, dNTPs, thermostable DNA polymerase enzyme and a passive reference probe was used. To amplify each of the genes the predesigned primers were used and sold by Life Technologies TaqMan ® Gene Expression Assays, Hs99999903-m1 (β-actin), Hs00900055-m1 (VEGF), Hs00972646-m1 (hTERT) y Hs00153408-m1 (c-MYC).
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